Paris, France, 16 May 2012 – Plans for a ground-breaking new study involving BioFreedom™, the polymer-free drug-coated stent (DCS) from Biosensors, were announced yesterday at EuroPCR by Principal Investigator Dr Philip Urban, Hôpital de la Tour, Geneva.
Los resultados obtenidos durante los seis meses posteriores al registro del dispositivo DELUX, que demuestran excelentes niveles de seguridad y eficacia para el balón liberador de paclitaxel Pantera Lux en más de 1.000 pacientes, fueron presentados por el Dr. Ralph Toelg, del Centro Clínico Cardiológico de Segeberger, Alemania y el Dr. Thomas Schmitz, del Hospital Elisabeth, Alemania, en el congreso EuroPCR 2012 que tuvo lugar en París la semana pasada. 20120524
Marco Costa, Cleveland, USA, presented two-year clinical results for the first-of-its-kind catheter-based Parachute Ventricular Partitioning device (CardioKinetix), a percutaneous ventricular restoration (PVR) therapy for patients with ischaemic heart failure. Data were presented on 18 May during a Trials, Registries and Late Breaking Science Hot Line session at EuroPCR.
Paris, France, 18 May 2012 – New long-term data from the DIVERGE study, presented yesterday at EuroPCR 2012 by Dr. John Ormiston, showed that the use of the Axxess™ drug-eluting stent (DES) for the treatment of complex coronary bifurcation lesions resulted in low levels of both MACE and VLST over a four-year period. Axxess™ is a self-expanding bifurcation stent which releases Biolimus A9™ from an abluminal biodegradable polymer coating.
PARIS & MENLO PARK, Calif., May 18, 2012 (BUSINESS WIRE) -- CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced two-year clinical results for the first-of-its-kind catheter-based Parachute(TM) Ventricular Partitioning Device, a Percutaneous Ventricular Restoration (PVR) therapy for patients with ischemic heart failure. Results were presented today during a Trials, Registries and Late Breaking Science Hot Line session at the 2012 EuroPCR Conference in Paris by Marco Costa, M.D., Ph.D., director of the Interventional Cardiovascular Center and the Research and Innovation Center at the Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University in Cleveland, Ohio.
NATICK, Mass., May 18, 2012 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent System in treating de novo coronary lesions in small coronary vessels. Analysis of the data was presented today at the annual EuroPCR Scientific Program in Paris.
PARIS -- The Parachute, a percutaneous device that walls off part of the left ventricle to help failing hearts, appears to have a big impact on outcomes, pilot study results showed.
The next generation of drug-eluting stents that do a disappearing act, whether with a biodegradable polymer or an entirely bioabsorbable platform, appears to be holding up to conventional stents over the short term.
PARIS -- Computer projections of the impact of stenting on cardiac ischemia measured by a specialized CT imaging technique appear accurate and could help with planning out placement, researchers found.
Lead investigator, Dariusz Dudek, Jagiellonian University, Krakow, Poland, presented positive three-year results from the extended follow-up MAGICAL trial at a InspireMD-sponsored symposium at EuroPCR.
Warfarin fared no better than aspirin at reducing the combined risk of brain hemorrhage, stroke, or death for heart-failure patients in normal rhythm, according to the results of a study published in the New England Journal of Medicine.
May 17, 2012 (Paris, France) — New data unveiled at EuroPCR 2012 yesterday are offering a fresh snapshot of just how quickly the number of TAVI procedures is increasing in Europe and where these are taking place. Since the first devices were approved in Europe in 2007, Germany has led the continent in implantations: by 2011, Germany hospitals had implanted a full 43% of all TAVI devices in Europe, the same proportion it held in 2010, as reported by heartwire last November. In a distant second place was France, with 13% of procedures, followed by Italy and the UK/Ireland, with 10% and 7%, respectively.
PARIS -- Statin treatment before percutaneous coronary intervention (PCI) reduces cardiac injury from the procedure and boosts longer term outcomes, Italian researchers affirmed.
Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis.
Results from the multicentre, randomised, controlled BELLO and PACIFIER trials were presented on 16 May at EuroPCR 2012. Data shows statistically significant advantages of using an IN.PACT drug-eluting balloon (Medtronic) over a corresponding conventional treatment for coronary and peripheral artery disease, respectively.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos